Central nervous system prophylaxis in mantle cell lymphoma

Gatt, Moshe E.; Grisaro, Sigal

doi:10.1182/blood-2009-09-245027

Cited by 4 publications

(2 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The role of central nervous system (CNS) prophylaxis in diffuse large B-cell lymphoma (DLBCL) 1,2 and mantle cell lymphoma 3,4 has been addressed in recent Blood issues. The role of CNS prophylaxis is still controversial, particularly after the introduction of immunochemotherapy.…”

mentioning

confidence: 99%

Central nervous system prophylaxis in peripheral T-cell lymphoma

Pro

Perini

2010

Blood

View full text Add to dashboard Cite

mentioning

confidence: 99%

Central nervous system prophylaxis in peripheral T-cell lymphoma

Pro

Perini

2010

Blood

View full text Add to dashboard Cite

“…УУР C (УДД 5). • Пациентам моложе 65 лет с верифицированной ЛКМ с бластоидным вариантом заболевания, гиперлейкоцитозом и/или при наличии симптомов вовлечения ЦНС рекомендуется профилактика нейролейкемии -спинномозговые пункции с введением стандартного набора препаратов в спинномозговой канал в соответствии с рекомендациями для агрессивных В-клеточных нефолликулярных лимфом с высоким риском поражения ЦНС [3,36]. УУР С (УДД 5).…”

Section: локальные (I-ii) стадииunclassified

Mantle cell lymphoma

et al. 2020

View full text Add to dashboard Cite

show abstract

Risk factors of central nervous system relapse in mantle cell lymphoma

Conconi

Franceschetti

Lobetti-Bodoni

et al. 2013

Leukemia & Lymphoma

View full text Add to dashboard Cite

Central nervous system (CNS) relapse has not been extensively studied in mantle cell lymphoma (MCL). We retrospectively analyzed the risk factors and pattern of CNS relapse in consecutive patients with MCL. We identified 142 cases of MCL treated from 1980 to 2011. Median age at diagnosis was 68 years; 82% of patients had advanced stage; extranodal disease was reported in 89% of cases and high serum lactate dehydrogenase (LDH) in 40%. Fourteen patients (10%) did not receive treatment at diagnosis. Chemotherapy was administered to 125 patients (88%), in 21 cases (15%) including drugs penetrating into the CNS or given intrathecally; 49 patients (35%) had rituximab. Ten patients had front-line autologous transplant. After a median follow-up of 7.9 years, CNS relapse occurred in 11 cases (7.8%) at a median of 13.8 months. Actuarial risk of CNS relapse was higher in patients with elevated LDH (p = 0.002), higher International Prognostic Index (IPI) score (p = 0.018) and blastoid histology (p < 0.0001). Blastoid histology retained significance at multivariate analysis. Median survival after CNS relapse was 6.3 months. No front-line treatment reduced the risk of CNS relapse. Our analysis confirms the poor outcome of MCL after CNS relapse and may allow the identification of patients needing prophylaxis of CNS relapse.

show abstract

Central nervous system prophylaxis in mantle cell lymphoma

Cited by 4 publications

References 7 publications

Central nervous system prophylaxis in peripheral T-cell lymphoma

Central nervous system prophylaxis in peripheral T-cell lymphoma

Mantle cell lymphoma

Risk factors of central nervous system relapse in mantle cell lymphoma

Contact Info

Product

Resources

About